AZN Looks 10.4% Undervalued on GF Value™ as Dividend Sustainability Shines

gurufocus.com · 2026-09-05

On September 05, 2026, AstraZeneca PLC (NYSE: AZN) received accelerated FDA approval for Etcamah (camizestrant), expanding treatment options for advanced breast

TickrTrends take: AstraZeneca trades at a valuation discount according to GuruFocus metrics, which aligns with TickrTrends' current undervalued assessment for the Healthcare sector company. The sustainability of the company's dividend payments represents a factor supporting the current valuation perspective, as consistent capital returns can indicate financial stability and cash generation capacity. Investors focused on valuation multiples should monitor whether AZN maintains its dividend coverage ratios and whether the stock's valuation gap persists as earnings and market conditions evolve.

Read the full story at gurufocus.com →